JP6756156B2 - Oral composition - Google Patents

Description

The present invention relates to an oral composition having an excellent effect of suppressing hypersensitivity and preventing or suppressing periodontal disease, which imparts a high bactericidal activity against periodontal disease-causing bacteria as well as an effect of suppressing hypersensitivity and promoting blood circulation in the gingiva.

Hypersensitivity in the oral cavity is caused by the exposure of a part of the dentin of the tooth, but it is also possible that the periodontal disease progresses and the periodontal disease and gums become inflamed and the gums regress. It is one of the causes. For this reason, a preparation that cares for both hypersensitivity and periodontal disease, that is, suppresses hypersensitivity and at the same time prevents or suppresses periodontal disease, which is a factor of gum retraction, is effective. Although an oral composition containing the above is commercially available, there is room for improvement in terms of effect, and further improvement is desired.

Aluminum lactate has a dentin tube blocking action and is effective as a hypersensitivity inhibitor.
In addition, a bactericidal agent for sterilizing periodontal disease-causing bacteria is an important component for the prevention and suppression of periodontal disease. Etc. are used.
On the other hand, tocopherol or its derivative, which has the effect of promoting blood circulation in the gingiva and suppressing inflammation, is also effective in preventing the regression of the gums due to periodontal disease, and if tocopherol or its derivative is used together with a bactericidal agent, the bactericidal action and blood circulation It is considered that further improvement of the effect can be expected by the promoting action.

Patent Document 1 (Patent No. 55979970) contains aluminum lactate and isopropylmethylphenol, a specific fragrance component, and sodium lauryl sulfate as an anionic surfactant, and has excellent hypersensitivity-suppressing action and biofilm bactericidal activity. Although a dentifrice composition having no dislike is proposed, a composition to which tocopherol or a derivative thereof is specifically added is not described. Further, in Patent Document 2 (Japanese Unexamined Patent Publication No. 7-291844), aluminum lactate, tocopherol nicotinate, chlorhexidine hydrochloride, and lauryl as examples of oral compositions having preventive and therapeutic effects on hypersensitivity and periodontal disease. Although toothpaste containing sodium sulfate has been described, its effect on periodontal disease has not been investigated, and Patent Document 3 (Japanese Unexamined Patent Publication No. 2001-172146) describes a formulation having an excellent effect of suppressing dentin hypersensitivity. An example toothpaste contains aluminum lactate, tocopherol acetate, cetylpyridinium chloride, and sodium lauryl sulfate, but it is unclear because there is no mention of its effects on periodontal disease such as bactericidal activity.

Japanese Patent No. 55979970 Japanese Unexamined Patent Publication No. 7-291844 Japanese Unexamined Patent Publication No. 2001-172146 Japanese Unexamined Patent Publication No. 2013-119520 Japanese Unexamined Patent Publication No. 2008-143825

However, even if tocopherol or a derivative thereof is added to the oral composition in addition to aluminum lactate and a bactericide, a satisfactory effect of preventing or suppressing hypersensitivity and periodontal disease cannot be obtained, and improvement of the effect is an issue. It was.

The present invention has been made in view of the above circumstances, and is excellent in that tocopherol or a derivative thereof is blended together with aluminum lactate and a bactericide to provide a high hypersensitivity suppressing effect, a gingival blood circulation promoting effect, and a high periodontal disease-causing bactericidal activity. An object of the present invention is to provide an oral composition having a preventive or suppressive effect on hypersensitivity and periodontal disease.

As a result of diligent studies to achieve the above object, the present inventors have made an oral composition in which tocopherol or a derivative thereof is blended with aluminum lactate, a bactericide, and acyltaurine, an acylamino acid, or an acyl amino acid as an anionic surfactant. By blending these salts with alginic acid or an alkali metal salt thereof, it is possible to secure high bactericidal activity against periodontal disease-causing bacteria while suppressing bitterness, and a remarkable effect on the above-mentioned problems can be obtained. I found. That is, in the present invention, the oral composition containing (A) aluminum lactate, (B) bactericide, (C) tocopherol and / or a derivative thereof is selected from (D) acyl taurine, acyl amino acids and salts thereof. By blending 0.8 to 1.5% by mass of one or more anionic surfactants, and 0.5 to 1.5% by mass of (E) alginic acid and / or its alkali metal salt, (A) , (B), (C) are effectively expressed, and the effect of suppressing hypersensitivity of tooth dentin and the effect of promoting blood circulation in the gingiva as well as the excellent bactericidal activity of periodontal disease-causing bacteria are given. It has the effect of preventing or suppressing hypersensitivity and periodontal disease, suppresses the bitterness derived from component (D), and can impart appropriate extrudability that can be easily extruded from the container even after low-temperature storage, resulting in hypersensitivity and periodontal disease. It has been found that a suitable preparation for the prevention or control of a disease can be provided, and the present invention has been made.

More specifically, in the oral composition, it is difficult to blend a plurality of components having different structures and properties from each other and to sufficiently and effectively express their various effects. When tocopherol or a derivative thereof is blended with aluminum lactate and a bactericidal agent in the oral composition, the bactericidal activity is reduced. For example, when isopropylmethylphenol is blended as a bactericidal agent, the biofilm permeation bactericidal activity is reduced. It was found that the decrease was remarkable in the composition containing sodium lauryl sulfate, which is a common anionic surfactant as a foaming agent. Therefore, as a result of proceeding with studies to improve the bactericidal activity, it was possible to prevent a decrease in the bactericidal activity by using sodium lauroylmethyltaurine instead of sodium lauryl sulfate. However, in this case, the bitterness derived from sodium lauroylmethyltaurine was strongly expressed, which had a great adverse effect on the usability. Therefore, as a result of further studies to improve the bactericidal activity without developing such bitterness, the binder (E) is obtained by blending the component (E) with the component (D). The component alginic acid and / or its alkali metal salt exerts an unexpected action as a bitterness masking agent, suppresses the bitterness derived from the component (D) without enhancing it, and improves the bactericidal power derived from the component (B). As a result, the above-mentioned exceptionally remarkable action and effect could be imparted by the combination of the components (A), (B), (C), (D), and (E).
It should be noted that Patent Documents 1 to 3 do not specifically describe the use of the components (D) and (E) in combination. Further, in Patent Document 4 (Japanese Patent Laid-Open No. 2013-119520), sodium lauroylmethyltaurine and sodium alginate are blended in an aluminum lactate-containing dentifrice composition for improving foaming and liquid separation, and Patent Document 5 (Japanese Patent Laid-Open No. 2008) -143825) is a suppression of off-flavor and off-taste of isopropylmethylphenol by l-menthol, sodium chloride and lauryl sulfate. From Patent Documents 1 to 5, it is unpredictable to improve the bactericidal activity and suppress the bitterness by combining the components (A), (B) and (C) with the components (D) and (E).

Therefore, the present invention provides the following oral compositions.
(A) Aluminum lactate,
(B) Fungicide,
(C) Tocopherol and / or its derivatives,
(D) One or more anionic surfactants selected from acyl taurine, acyl amino acids and salts thereof,
It contains (E) alginic acid and / or an alkali metal salt thereof, and the content of the component (D) is 0.8 to 1.5% by mass and the content of the component (E) is 0.5 to 1.5% by mass. An oral composition characterized by being.

According to the present invention, the effect of suppressing hypersensitivity, the effect of promoting blood circulation in the gingiva, and the effect of preventing or suppressing periodontal disease, which gives a high bactericidal activity against periodontal disease-causing bacteria, are exhibited, and the bitterness is suppressed. It is possible to provide an oral composition suitable for prevention or suppression of hypersensitivity and periodontal disease, which has a good feeling of use and good extrudability from a container.

Hereinafter, the present invention will be described in more detail. The oral composition of the present invention comprises (A) aluminum lactate, (B) bactericide, (C) tocopherol and / or a derivative thereof, (D) acyl taurine, acyl amino acid and It contains one or more anionic surfactants selected from these salts, (E) alginic acid and / or an alkali metal salt thereof.

(A) Aluminum lactate is a water-soluble hypersensitivity inhibitor having an ivory tube blocking action. The blending amount is preferably 0.5 to 10% (mass%, the same applies hereinafter) of the entire composition, and more preferably 1 to 5%. The larger the amount, the more the hypersensitivity can be suppressed, but 10% or less is suitable for preventing the development of its own metallic taste.

(B) The bactericidal agent may be any one that can be used for the oral cavity. Specific examples thereof include nonionic disinfectants such as isopropylmethylphenol (biosol), thymol, triclosan, and hinokithiol, and cationic disinfectants such as benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, and chlorhexidine gluconate. One or more may be used. Among them, a non-ionic bactericidal agent, particularly isopropylmethylphenol, exhibits oral biofilm osmotic bactericidal activity and is preferable because of its excellent bactericidal activity.
The blending amount of the bactericidal agent (B) is preferably 0.001 to 1%, more preferably 0.05 to 0.5% of the total composition. The larger the amount, the higher the bactericidal activity, but 1% or less is suitable for preventing the development of its own sarcasm.

Tocopherol and / or its derivative of the component (C) is a poorly water-soluble component that prevents or suppresses periodontitis / gingival inflammation by promoting blood circulation in the gingiva.
Specific examples thereof include tocopherol, tocopherol acetate, tocopherol nicotinate, tocopherol succinate and the like, and one or more of these can be used. Of these, tocopherol acetate, which is an acetate ester of tocopherol, is preferable.

The blending amount of (C) tocopherol and / or a derivative thereof is preferably 0.05 to 2%, more preferably 0.1 to 1% of the total composition. The larger the amount, the higher the blood circulation promoting effect, but 2% or less is suitable for preventing the development of its own oily odor.

In the present invention, the bactericidal activity is improved and the bactericidal activity is improved by using (D) an anionic surfactant selected from acyl taurine, acyl amino acids and salts thereof in combination with (E) alginic acid and / or an alkali metal salt thereof. , Bitterness is suppressed, and the extrudability from the container is also improved. If the component (D) is not contained, the bactericidal activity is inferior, and if the component (E) is not contained, the bitterness is not suppressed, and the preparation becomes soft and easily loses its shape when extruded from the container and placed on a toothbrush. , Easy to drip and inferior in usability.

The component (D), acyl taurine, acyl amino acid and salts thereof, impart foamability as an anionic surfactant and exert a bactericidal activity improving action. Preferably, it is selected from an acyl taurine salt, an acyl glutamic acid salt and an acyl alanine salt having an acyl group having 8 to 18 carbon atoms, particularly 12 to 16, and more preferably an acyl taurine salt.
Specific examples of the acyl taurine salt include methyl taurine salts such as lauroyl methyl taurine salt, coconut oil fatty acid methyl taurine salt, and myristyl methyl taurine salt. Examples of the acylglutamic acid salt include lauroyl glutamate and myristol glutamate, and examples of the acylalanine salt include methylalanine salts such as lauroylmethylalanine salt. As the salt, alkali metal salts such as sodium salt and potassium salt, particularly sodium salt is preferable. One or more of these may be used, among which sodium lauroylmethyl taurine, sodium lauroyl glutamate, sodium myristoylation glutamate, especially sodium lauroyl methyl taurine, improves bactericidal activity, especially biofilm penetrating bactericidal activity and suppresses bitterness. It is suitable from the viewpoint of.

The blending amount of the component (D) is 0.8 to 1.5% of the entire composition, particularly preferably 0.8 to 1.2%, and more preferably 0.9 to 1.2%. If it is less than 0.8%, the bactericidal activity is not improved, and if it exceeds 1.5%, the bitterness of itself becomes too strong and the bitterness cannot be suppressed.

The component (E), alginic acid and / or its alkali metal salt, is a bitter masking agent and, as a binder, appropriately maintains the extrudability of the preparation from the container.
Specific examples thereof include sodium alginate, and the viscosity of the 2% aqueous solution is preferably 1,000 to 4,000 mPa · s, more preferably 2,000 to 4,000 mPa · s. The viscosity is a value measured by a BL type rotational viscometer (rotor No. 3, 12 rpm, 25 ° C., measurement time 3 minutes).
As such sodium alginate, a commercially available product, for example, a commercially available product such as Kimika algin (trade name) manufactured by Kimika Co., Ltd. can be used.

The blending amount of (E) alginic acid and / or the alkali metal salt thereof is 0.5 to 1.5%, preferably 0.6 to 1.3%, and more preferably 0.7 to 1 of the entire composition. .2%. If it is less than 0.5%, the bitterness is not suppressed, and if it exceeds 1.5%, the preparation becomes too hard after storage at low temperature and the extrudability from the container is inferior.

Further, (D) / (E) indicating the blending ratio of the component (D) and the component (E) is preferably 0.53 to 3, more preferably 0.6 to 2.5, still more preferably, as a mass ratio. Is 0.6 to 2, particularly preferably 0.75 to 1.7. Within this range, the bactericidal activity is more excellent and the bitterness is sufficiently suppressed. If it is less than 0.53, the bactericidal activity may be low or the extrudability from the container may be poor. If it exceeds 3, the bitterness may not be sufficiently suppressed.

Further, in the present invention, an anionic surfactant other than the component (D) may be blended as long as the effect is not hindered, but the blending amount of the alkyl sulfate such as sodium lauryl sulfate is 0 in the entire composition. It is preferably 0.8% or less, particularly 0.5% or less, particularly 0.1% or less, and more preferably no compounding (0%).

Further, a binder other than (E) alginic acid and / or an alkali metal salt thereof can be added as long as the effect of the present invention is not impaired. Specifically, water-soluble polymer compounds such as xanthan gum, carrageenan, sodium carboxymethyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, sodium polyacrylate, polyvinylpyrrolidone, and polyvinyl alcohol as organic binders. Can be mentioned. When these binders are added, the total amount of the organic binder including the component (E) is within the range of 0.5 to 3%, particularly 0.6 to 2.5% of the entire composition. Is preferable. Further, the mass ratio of the component (E) / (total amount of the binder including the component (E)) is preferably in the range of 0.5 to 1, particularly 0.6 to 1.
Further, 0.1 to 10%, particularly 0.5 to 7% of thickening anhydrous silicic acid, which is an inorganic thickener, may be blended.

The oral composition of the present invention is suitable as a dentifrice, particularly a dentifrice. In addition, known components other than the above can be arbitrarily added depending on the dosage form, purpose of use, and the like. For example, abrasives, thickeners, surfactants and, if necessary, sweeteners, colorants, fragrances, medicinal ingredients, pH adjusters and the like can be mentioned.

Examples of the abrasive include silica-based abrasives such as silicon dioxide, silica gel, aluminosilicate, and zirconosilicate, calcium phosphate-based abrasives, and calcium carbonate. The blending amount is usually 2 to 50%, particularly 10 to 30%.

Examples of the viscous agent include sugar alcohols such as sorbitol, xylit, and reduced starch saccharified product, propylene glycol, and polyethylene glycol having an average molecular weight of 200 to 6,000 (average molecular weight described in the pharmaceutical non-medicinal product raw material standard 2006; the same applies hereinafter). Examples thereof include polyhydric alcohols such as ethylene glycol. The blending amount is usually 5 to 50%, particularly 20 to 45%.

Examples of the surfactant include nonionic surfactants such as polyoxyethylene hydrogenated castor oil and polyoxyethylene alkyl ether, and amphoteric surfactants such as fatty acid amide propyl betaine. These may be non-blended (0%), but when blended, the blending amount is preferably 0.1 to 3%.

Examples of the sweetening agent include sodium saccharin, and examples of the coloring agent include blue No. 1, yellow No. 4, titanium dioxide and the like.

As the fragrance, a fragrance composition that can be used alone or in combination of a plurality of fragrance components that can be used in the oral composition can be used.
For example, peppermint oil, sparemint oil, anise oil, eucalyptus oil, winter green oil, cassia oil, clove oil, thyme oil, sage oil, lemon oil, orange oil, peppermint oil, cardamon oil, coriander oil, mandarin oil, lime oil. , Lavender oil, rosemary oil, laurel oil, camo mill oil, caraway oil, majorum oil, bay oil, lemongrass oil, origanum oil, pine needle oil, neroli oil, rose oil, jasmine oil, grapefruit oil, sweetie oil, Natural fragrances such as yuzu oil, iris concrete, absolute peppermint, absolute rose, orange flower, and processing of these natural fragrances (pre-reservoir cut, rear-reservoir cut, distilling, liquid extraction, essence, powder fragrance) Etc.) and menthol, carboxylic, anator, cineole, methyl salicylate, synamic aldehyde, eugenol, 3-l-mentoxypropane-1,2-diol, timol, linalol, linaryl acetate, limonene, menton, Menthylacetate, N-substituted-paramentan-3-carboxamide, pinen, octylaldehyde, citral, pregon, calvier acetate, anisaldehyde, ethylacetate, ethylbutyrate, allylcyclohexanepropionate, methylanthranilate, ethylmethylphenyl Single flavors such as glycidate, vanillin, undecalactone, hexanal, butanol, isoamyl alcohol, hexenol, dimethylsulfide, cycloten, furfural, trimethylpyrazine, ethyllactate, ethylthioacetate, as well as strawberry flavor, apple flavor, banana flavor, Known flavoring materials used in oral compositions, such as pineapple flavors, grape flavors, mango flavors, butter flavors, milk flavors, fruit mix flavors, and tropical fruit flavors, can be used in combination. It is not limited to the fragrances described in the examples. Although the blending amount is not particularly limited, the above-mentioned fragrance material is preferably used in the composition at 0.000001 to 1%, and the fragrance for perfume using the above-mentioned fragrance material is 0.1 in the composition. It is preferable to use ~ 2%.

In addition to the components (A), (B), and (C), the medicinal properties include potassium nitrate, which is a hypersensitivity-suppressing component, fluorides such as sodium fluoride and sodium monofluorophosphate, tranexamic acid, allantin, and chloride. Sodium, ε-aminocaproic acid, etc. may be blended. These can be added in an effective amount as long as the effects of the present invention are not impaired.

A pH adjuster may be added, and examples thereof include alkali metal hydroxides such as sodium hydroxide and hydrogen phosphate salts such as monosodium dihydrogen phosphate.
The liquid medium is usually water, and a monohydric lower alcohol having 1 to 3 carbon atoms such as ethanol may be added.

Hereinafter, the present invention will be specifically described with reference to Examples and Comparative Examples, but the present invention is not limited to the following Examples. In the following examples,% indicates mass% unless otherwise specified.

[Examples, comparative examples]
A dentifrice composition (dentifrice) having the compositions shown in Tables 1 and 2 was prepared by a conventional method and evaluated by the following method. The results are also shown in the table.
The viscosity of the 2% aqueous solution of sodium alginate used (BL type rotational viscometer, rotor No. 3, 12 rpm, 25 ° C., measurement time 3 minutes) is within the range of about 3,000 mPa · s.
Further, it was confirmed that both the dentifrice compositions of Examples and Comparative Examples had the effect of suppressing hypersensitivity derived from the component (A) and the effect of promoting blood circulation of the gingiva derived from the component (C).

(1) Evaluation method of bactericidal activity (periodontal disease biofilm osmotic bactericidal activity) A human obtained by filtering a hydroxyapatite (HA) plate (manufactured by HOYA Corporation) having a diameter of 7 mm and a thickness of 3.5 mm with a 0.45 μm filter. The one treated with unstimulated saliva for 4 hours was used as a model biofilm preparation carrier. The culture solution was 5 mg / L of hemin (manufactured by Sigma) and 1 mg / L of vitamin K (manufactured by Wako Pure Chemical Industries, Ltd.) in a solution prepared by dissolving 30 g of trypticase soybros (manufactured by Difco) in 1 L of purified water. Was used.
The oral bacteria used to prepare the model biofilms were all purchased from the American Type Culture Collection (ATCC), and as indigenous bacteria in the oral cavity, Streptocaccus gordonii ATCC51656 strain and Actinomyces naeslandi ATCC51655 strain, pathogenic Porphyromonas gingivalis ATCC33277 strain was used as a bacterium. Each of these three bacterial species was inoculated into the above-mentioned culture solution at 2 × 10 ⁷ cfu / mL (colony forming units), and together with the saliva-treated HA carrier, at 37 ° C. under anaerobic conditions (80 vol% nitrogen, 10 vol% carbon dioxide). The cells were continuously cultured in carbon (10 vol% hydrogen) for 2 weeks (the substitution rate of the culture solution was 10 vol%), and a model biofilm containing three bacterial species was formed on the surface of HA.

The formed model biofilm was immersed in 2 mL of an evaluation agent (a supernatant obtained by adding 2 times the mass of artificial saliva to a dentifrice composition, dispersing it, and then centrifuging it) for 3 minutes, and washed 6 times with 1 mL of sterile physiological saline. did. Then, 4 mL of sterile physiological saline was added to disperse the model biofilm by sonication (200 μA, 10 seconds), and 50 μL of this was placed in a trypticase soy agar medium (manufactured by Difco) containing 10% cotton sheep defibrotic blood. The cells were smeared and anaerobically cultured (80 vol% nitrogen, 10 vol% carbon dioxide, 10 vol% hydrogen) until colonies could be confirmed with the naked eye. The number of black colonies of the grown Porphyromonas gingivalis was counted, the number of viable bacteria (cfu) was determined, and the biofilm (BF) osmotic bactericidal activity was determined according to the following evaluation criteria.
Evaluation criteria ⊚: cfu is less than 10 ⁵ ○: cfu is 10 ⁵ or more and less than 10 ⁶ Δ: cfu is 10 ⁶ or more and less than 10 ⁷ ×: cfu is 10 ⁷ or more

(2) Evaluation method for lack of bitterness Ten specialist panelists evaluated the bitterness felt when the dentifrice composition was placed on a toothbrush and the oral cavity was washed by a usual method according to the following scoring criteria. From the average value of the evaluation points of 10 people, the absence of bitterness was judged according to the following criteria.
Rating criteria;
4 points: No bitterness 3 points: Almost no bitterness 2 points: Bitterness 1 point: Very bitterness Judgment criteria;
⊚: Average score 3.5 points or more ○: Average score 3.0 points or more and less than 3.5 points Δ: Average score 2.0 points or more and less than 3.0 points ×: Average score less than 2.0 points

(3) Ease of extrusion from a container 50 g of a dentifrice composition was filled in a laminated tube having a diameter of 8 mm, and three of each composition were stored at −5 ° C. for 1 month. Ten professional panelists extruded the dentifrice composition from the container and evaluated the degree of extruded hardness on a four-point scale according to the following scoring criteria. From the average value of the evaluation points of 10 people, the ease of extrusion from the container after low-temperature storage was determined according to the following criteria.
Rating criteria;
4 points: Can be extruded smoothly from the tube 3 points: Can be extruded slightly smoothly from the tube 2 points: Slightly difficult to extrude from the tube 1 point: Difficult to extrude from the tube Judgment criteria;
⊚: Average score 3.5 points or more ○: Average score 3.0 points or more and less than 3.5 points Δ: Average score 2.0 points or more and less than 3.0 points ×: Average score less than 2.0 points

Claims (9)

(A) 1 to 5% by mass of aluminum lactate,
(B) 0.05 to 0.5% by mass of isopropylmethylphenol ,
(C) Tocopherol and / or its derivative in 0.1 to 1% by mass ,
(D) 0.8 to 1.5% by mass of one or more anionic surfactants selected from acyl taurine, acyl amino acids and salts thereof.
(E) 0.5 to 1.5% by mass of alginic acid and / or its alkali metal salt
An oral composition containing , and the content of (F) sodium lauryl sulfate is 0 to 0.5% by mass . Component (D) of the anionic surfactant is acyl taurates number of carbon atoms of the acyl group is from 8 to 18, the oral composition of claim 1 wherein at least one member selected from acyl glutamates and acyl alanine salts Stuff. The oral composition according to claim 2, wherein the anionic surfactant of the component (D) is an acyl taurine salt having an acyl group having 8 to 18 carbon atoms. (C) The oral composition according to any one of claims 1 to 3, wherein the tocopherol and / or a derivative thereof is one or more selected from tocopherol, tocopherol acetate, tocopherol nicotinate and tocopherol succinate. .. (E) Any one of claims 1 to 4, wherein the alginic acid and / or the alkali metal salt thereof is sodium alginate, and the viscosity of the 2% by mass aqueous solution thereof at 25 ° C. is 1,000 to 4,000 mPa · s. The above-mentioned oral composition. The oral cavity according to any one of claims 1 to 5 , wherein (D) / (E) indicating the mixing ratio of the component (D) and the component (E) is 0.6 to 2.5 as a mass ratio. Composition. ( F) The oral composition according to any one of claims 1 to 6 , wherein the content of sodium lauryl sulfate is 0 % by mass. The oral composition according to any one of claims 1 to 7 , which is a dentifrice. The oral composition according to any one of claims 1 to 8 , which is for suppressing hyperesthesia and periodontal disease.